THE OPIOID CRISIS AND BEYOND:

EPIDEMIOLOGY AND PUBLIC HEALTH PERSPECTIVES ON SUBSTANCE USE DISORDERS

PRNworld

THE OPIOID CRISIS AND BEYOND:

EPIDEMIOLOGY AND PUBLIC HEALTH PERSPECTIVES ON SUBSTANCE USE DISORDERS

ANCC Accredited NCPD Hours: 1 hrs

Target Audience: RN/APRN

NEEDS ASSESSMENT

Substance Use Disorders (SUDs), particularly Opioid Use Disorder (OUD), constitute a pervasive and escalating public health emergency in the United States and globally. According to the 2022 National Survey on Drug Use and Health (NSDUH), an estimated 48.7 million individuals aged 12 and older, approximately one in six Americans, met the criteria for an SUD, with opioid misuse contributing disproportionately to morbidity and mortality.

Despite the growing burden of SUDs, significant gaps remain in the clinical preparedness of healthcare professionals, especially nurses and advanced practice providers, to identify, assess, and respond to the complexities of these conditions. Many clinicians lack current, evidence-based training in the epidemiological trends, diagnostic criteria (as defined in DSM-5-TR), and structural determinants that shape disparities in access, outcomes, and long-term recovery.

Moreover, the rapid evolution of the opioid epidemic driven by the proliferation of synthetic opioids like fentanyl demands a more nuanced understanding of population-level data, emerging public health threats, and policy-level interventions. Without robust continuing education, clinicians may be ill-equipped to advocate for equitable care, apply trauma-informed principles, or engage in culturally responsive practices.

There is a critical need to build workforce capacity through targeted education that emphasises data-driven insights, public health frameworks, and the social determinants of health. Empowering clinicians with these competencies is essential to improving identification, prevention, and management of

SUDs across all care settings and to reducing the human and societal toll of this ongoing crisis.

OBJECTIVES

By the end of this module, participants will be able to:

- **Describe** the current epidemiology and societal burden of substance use disorders (SUDs), including opioid-related morbidity and mortality.
- **Interpret** national and global surveillance data (e.g., NSDUH, CDC, WHO) to identify emerging trends in substance misuse and overdose deaths.
- **Recognise** disparities in substance use outcomes by race, ethnicity, gender, socioeconomic status, and geography.
- **Apply** DSM-5-TR diagnostic criteria to identify and categorise the severity of SUDs.
- **Identify** structural and systemic barriers contributing to underdiagnosis and treatment inequity in vulnerable populations.

GOAL

To enhance health care professionals' understanding of the epidemiology, diagnostic criteria, and public health burden of substance use disorders, especially OUD, enabling evidence-based, equitable, and informed care delivery across diverse populations.

INTRODUCTION

Substance Use Disorders (SUDs) represent one of the most pressing and complex challenges in modern healthcare. Defined by the DSM-5-TR as a maladaptive pattern of substance use leading to significant clinical impairment or distress, SUDs encompass a wide spectrum of substances, including opioids, alcohol, stimulants, and sedatives, and affect individuals across all ages, backgrounds, and regions. In particular, Opioid Use Disorder (OUD) has emerged as a dominant contributor to the national crisis, accounting for the majority of overdose-related deaths and driving up rates of healthcare utilisation, disability, and premature mortality.

The opioid epidemic continues to evolve in devastating waves, shifting from prescription opioid misuse to heroin use, and now to the widespread infiltration of illicitly manufactured fentanyl and analogues. With nearly 48.7 million individuals in the U.S. alone affected by a substance use disorder (NSDUH, 2022), the urgency for a public health-oriented, data-driven response has never been greater.

This module provides clinicians and all health care professionals with a foundational understanding of the epidemiology and public health implications of SUDs, with a particular

focus on opioid-related harms. Through the interpretation of national and global surveillance data, recognition of diagnostic criteria, and exploration of systemic disparities in care, participants will gain the essential knowledge to deliver equitable, evidence-based interventions. As frontline providers, nurses and advanced practice clinicians play a pivotal role in addressing this crisis, not only through clinical management but also by championing prevention, education, and policy change.

SUBSTANCE USE DISORDER (SUD) – DSM-5-TR DEFINITION

Substance Use Disorder (SUD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) as a problematic pattern of use of an intoxicating substance leading to clinically significant impairment or distress. This disorder can apply to a wide range of substances, including **alcohol, cannabis, opioids, stimulants, sedatives, hallucinogens, and tobacco.**

Key Features of SUD (DSM-5-TR)

- **Problematic Pattern of Use:** The individual continues using the substance despite significant substance-related problems.
- **Clinically Significant Impairment or Distress:** The pattern of use results in health issues, disability, or failure to meet major responsibilities at work, school, or home.

Diagnostic Criteria

A diagnosis of SUD is based on the presence of at least **two** of the following criteria within 12 months:

1. **Impaired Control:**
- Substance is often taken in larger amounts or over a longer period than intended.
- Persistent desire or unsuccessful efforts to cut down or control use.
- A great deal of time spent in activities necessary to obtain, use, or recover from the substance.
- Craving or a strong desire to use the substance.

2. **Social Impairment:**
- Recurrent use failing to fulfil major role obligations at work, school, or home.
- Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance.
- Important social, occupational, or recreational activities are given up or reduced because of use.

3. **Risky Use:**
- Recurrent use in situations in which it is physically hazardous.

- Continued use despite knowledge of having a persistent or recurrent physical or psychological problem likely to have been caused or exacerbated by the substance.

4. **Pharmacological Criteria:**

- **Tolerance:** Need for markedly increased amounts of the substance to achieve intoxication or the desired effect, or markedly diminished effect with continued use of the same amount.
- **Withdrawal:** Characteristic withdrawal syndrome for the substance, or the substance is taken to relieve or avoid withdrawal symptoms.

Severity Specifiers

Severity Specifiers

Mild	2-3 criteria met
Moderate	4-5 criteria met
Severe	6 or more criteria met

DSM-5-TR defines substance use disorder as a complex, multifaceted condition characterised by a problematic pattern of substance use leading to significant impairment or distress, diagnosed by meeting specific behavioural, social, and physiological criteria. The severity of the disorder is determined by the number of criteria met within 12 months.

EPIDEMIOLOGY OF OPIOID USE DISORDER (OUD) AND SUBSTANCE USE DISORDERS (SUDS)

Substance Use Disorders (SUDs) represent a pervasive and debilitating public health crisis, manifesting as chronic, relapsing conditions that exact a staggering toll on individuals, families, and societies worldwide. The most recent data from the 2022 National Survey on Drug Use and Health (NSDUH) underscores the alarming scale of this challenge in the United States, revealing that nearly 48.7 million individuals aged 12 and older, approximately one in every six people, grappled with a SUD in the past year. Within this vast landscape of addiction, Opioid Use Disorder (OUD) stands out as a particularly formidable adversary, afflicting roughly 5 million individuals and contributing disproportionately to the nation's soaring rates of morbidity and mortality. Beyond the profound personal suffering, the societal repercussions of SUDs are immense and far-reaching: they encompass colossal direct healthcare expenditures for emergency interventions, prolonged hospitalizations, and specialized behavioural health services; substantial indirect costs stemming from pervasive lost productivity, chronic disability, familial disintegration, and extensive entanglement with the criminal justice system; and devastating psychosocial consequences

that ripple through communities, manifesting as heightened instances of child neglect, domestic violence, widespread homelessness, and the insidious propagation of intergenerational trauma. These intertwined impacts underscore the urgent need for comprehensive, multi-faceted public health strategies to prevent, treat, and support recovery from SUDs, thereby mitigating their profound human and economic burden.

GLOBAL PERSPECTIVE

According to the **World Health Organisation (WHO)**, an estimated **60 million people worldwide** engaged in non-medical use of opioids in 2022, including substances such as heroin, morphine, and codeine. This global burden reflects widespread access to opioids, both licit and illicit, and reinforces the need for coordinated international efforts to reduce supply, demand, and associated harms.

PREVALENCE IN THE UNITED STATES

Opioid Use Disorder (OUD)

Opioid Use Disorder remains a significant and growing public health challenge. Recent prevalence models estimate that **6.7 to 7.6 million adults** in the United States are currently living with OUD. According to the **2021 National Survey on Drug Use and Health (NSDUH)**, approximately **5.6 million individuals aged 12 and older** met the diagnostic criteria for OUD. Globally, over **16 million people** are estimated to be affected by OUD, with approximately **2.1 million** residing in the United States, highlighting a substantial disease burden across healthcare systems.

Opioid Use Disorder Market Size & Trends

The global opioid use disorder market size was valued at USD 5.28 billion in 2024 and is projected to grow at a CAGR of 11.15% from 2025 to 2030. The expansion of the market is driven by the rising rates of substance use disorders, growing government efforts to address the crisis, and increased awareness of opioid use disorder treatments. These factors are anticipated to significantly boost market growth over the forecast period, fostering innovation and improving access to addiction care solutions.



Prescription Opioid Use Disorder (POUD)

Prescription Opioid Use Disorder refers to a pattern of opioid misuse (excluding heroin or other illicit opioids) that meets DSM-5-TR diagnostic criteria for substance use disorder. POUD is characterised by impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal).

- As of **2021**, an estimated **5.0 million people aged 12 or older** had a **POUD**, representing a significant subset of all opioid-related disorders.
- The transition from use to POUD is often gradual and associated with untreated or undertreated pain, repeated refills, and concurrent use of other substances.

Prescription Opioid Use and Misuse

Prescription opioids remain widely used for the treatment of acute and chronic pain, despite mounting concerns about misuse and dependence. According to the **2022 National Survey on Drug Use and Health (NSDUH)**:

- Approximately **8.5 million people aged 12 or older** in the United States reported using prescription pain relievers in the past year.
- Of those, **4.3 million (50.6%)** engaged in **misuse**, defined as using a medication in any way not directed by a doctor (e.g., using without a prescription, in greater amounts, or for the experience or feeling it causes).
- Common motivations for misuse include self-treatment of pain, euphoria-seeking, and managing emotional distress.





Overall Substance Use Disorders (SUDs)

In 2022, the NSDUH reported that **48.7 million individuals aged 12 and older,** representing **17.3% of the U.S. population**, had a substance use disorder in the past year. These disorders encompass a broad range of substances, including alcohol, cannabis, and opioids, and continue to contribute

significantly to morbidity, mortality, and social disruption.

Overdose Mortality and Trends

1. Drug Overdose Deaths:

In 2022, the United States recorded nearly **108,000 drug overdose deaths**, with **approximately 82,000 (76%)** involving opioids. The surge in mortality is primarily attributed to the proliferation of **illicitly manufactured synthetic opioids**, particularly **fentanyl**, which has dramatically altered the landscape of overdose risk. In 2021, **80,816 opioid-related overdose deaths** were reported, underscoring the persistent and escalating nature of the opioid epidemic.

2. Nonfatal Overdoses:

Projections from 2021 to 2023 estimated **over 5 million nonfatal** and **approximately 145,000 fatal opioid-involved overdoses** among individuals with OUD in the U.S., demonstrating the immense scale of preventable harm and the need for sustained intervention.





THE EVOLVING WAVES OF THE OPIOID EPIDEMIC IN THE UNITED STATES

The opioid epidemic in the United States has unfolded in a well-documented and increasingly devastating trajectory, marked by **three distinct waves**, each defined by a dominant opioid class and a corresponding surge in mortality.

- The **First Wave**, emerging in the **late 1990s**, was characterised by a dramatic increase in the prescribing and misuse of **prescription opioids** such as oxycodone and hydrocodone. This surge was largely driven by aggressive pharmaceutical marketing practices and a clinical shift toward the routine use of opioids for chronic non-cancer pain, despite limited evidence of long-term efficacy and safety.

- The **Second Wave**, beginning around **2010**, witnessed a significant rise in **heroin-related overdose deaths**. Many individuals who had developed dependence on prescription opioids transitioned to heroin due to its **lower cost and greater accessibility**, contributing to a rapid expansion of opioid use disorder (OUD) across diverse populations.
- The **Third Wave**, commencing in **2013 and continuing to the present day**, has been dominated by the widespread availability and use of **illicitly manufactured synthetic opioids**, primarily **fentanyl** and its analogues. These substances are **50 to 100 times more potent than morphine** and are often mixed with other drugs, frequently without the user's knowledge, dramatically increasing the risk of overdose.

This ongoing public health crisis has culminated in opioid overdose becoming the **leading cause of death among adults aged 18 to 45 in the United States**, surpassing fatalities from motor vehicle accidents, firearms, and many infectious diseases. The escalating lethality and complexity of this epidemic underscore the urgent need for a comprehensive, evidence-based, and multi-sectoral response.



UNDERSTANDING DISPARITIES IN SUBSTANCE USE DISORDER (SUD) OUTCOMES: A STRUCTURAL AND DEMOGRAPHIC PERSPECTIVE

The impact of substance use disorders (SUDs) is far from evenly distributed. Profound **disparities in incidence, treatment access, and outcomes** persist across race, ethnicity, geography, socioeconomic status, gender, and age groups. These inequities are not random; they are deeply rooted in **structural determinants of health**, including systemic racism, economic disadvantage, rural under-resourcing, and pervasive social stigma.

Understanding the nature and drivers of these disparities is essential for the development of **targeted, equitable, and effective public health interventions**.

1. Racial and Ethnic Disparities

While earlier phases of the opioid crisis disproportionately affected **White, non-Hispanic populations**, more recent data from the **Centres for Disease Control and Prevention (CDC)** highlight a troubling shift. **Black and American Indian/Alaska Native (AI/AN) communities now exhibit the highest rates of opioid-related overdose mortality per capita**.

This shift reflects the evolving epidemiology of substance use but also exposes longstanding systemic inequities in access to care, treatment engagement, and harm reduction resources. Simultaneously, **Latinx populations** often face significant barriers to care, including **language differences**, **immigration-related fears**, and a **lack of culturally competent services**, which limit engagement with SUD treatment.

Key Issues:

- Underrepresentation in MAT programs.
- Implicit bias and racism within healthcare settings.
- Cultural mismatches between providers and patients.



2. Socioeconomic Disparities

Low-income individuals are disproportion - ately affected by untreated or inadequately managed SUDs. Contributing factors include:

- **Lack of health insurance** or underinsurance.
- **Transportation barriers** to access treatment facilities.
- A **shortage of qualified providers** in economically disadvantaged regions.

In particular, access to **Medication-Assisted Treatment (MAT),** an evidence-based standard for treating Opioid Use Disorder (OUD), is significantly lower among individuals relying on publicly funded programs or living in poverty. These systemic access barriers result in delayed care, higher rates of complications, and poorer overall outcomes.

3. Geographic Disparities: The Rural Burden

Although the opioid crisis was once considered a predominantly urban issue, **rural communities are now experiencing overdose mortality rates equal to or exceeding those in urban centres**. Factors contributing to these disparities include:

- Fewer **harm reduction services** (e.g., syringe programs, naloxone distribution).
- Limited or **non-existent MAT programs**.
- Geographic isolation and **long travel distances** to treatment.

Rural hospitals and primary care providers often lack specialised addiction treatment capacity, and stigma within smaller communities may deter individuals from seeking help.

4. Gender Differences in SUD Patterns and Barriers

Gender-based differences in SUD development, expression, and treatment access are well-documented. While men are more likely to engage in **high-risk substance use**, women, particularly those of **reproductive age,** face:

- Heightened **stigma** related to substance use in pregnancy.
- **Fear of losing custody** or legal consequences.
- Lack of **childcare support** limits treatment participation.
- Underrepresentation in clinical trials leads to a **gender data gap** in treatment efficacy.

Tailoring services to meet the **unique psychosocial needs of women** is essential, particularly during pregnancy and postpartum periods.

5. Age-Related Vulnerabilities

Youth (ages 18–25) are at increased risk of **polysubstance use**, often driven by peer influence, neurodevelopmental vulnerability, and under-recognition of early symptoms. Engagement in treatment is commonly delayed due to:

- Lack of awareness.
- Stigma among peers.
- Insufficient youth-focused SUD programs.

At the other end of the spectrum, **older adults** are frequently **underdiagnosed** and **undertreated** due to:

- Ageist assumptions by clinicians.
- Misattribution of symptoms (e.g., confusion, falls) to ageing rather than substance use.
- Polypharmacy complications with prescription and non-prescription substances.

Addressing age-specific needs across the life span is crucial for early intervention and appropriate care.

MOVING TOWARD EQUITY IN SUD CARE

Reducing disparities in SUD outcomes requires a **comprehensive, interdisciplinary, and equity-focused strategy** that includes:

- Delivery of **culturally responsive, trauma-informed care**.
- Diversification of the **behavioural health workforce** to reflect the communities served.
- **Policy reforms,** such as Medicaid expansion to increase access in underserved populations.
- Continuous **clinician education** on implicit bias, structural racism, and evidence-based care models.

Investing in community partnerships, mobile treatment units, and peer support services can also reduce gaps in service delivery.

CONCLUSION

The epidemiology and public health burden of substance use disorders (SUDs), particularly Opioid Use Disorder (OUD), demand the sustained attention and informed response of healthcare professionals at every level. As demonstrated throughout this module, SUDs are not isolated clinical conditions; they are deeply rooted in social, economic, and structural determinants that influence both access to care and treatment outcomes.

By understanding the evolving trends in substance use, recognising disparities across demographic groups, and interpreting surveillance data from credible sources such as the NSDUH, CDC, and WHO, nurses and advanced practice providers are uniquely positioned to drive change. This includes advocating for equitable care, engaging in culturally responsive interventions, and integrating evidence-based practices such as Medication-Assisted Treatment (MAT) into routine care settings.

As frontline clinicians, your role is pivotal not only in identifying and managing SUDs but also in mitigating stigma, addressing gaps in care, and championing prevention efforts. Continued education and interprofessional collaboration will be essential to overcoming the complex challenges posed by this public health crisis and ensuring improved outcomes for individuals, families, and communities impacted by substance use.

REFERENCES

1. National Survey on Drug Use and Health (NSDUH). (2022). *Substance Use and Mental Health Estimates*. https://www.samhsa.gov/data/
2. Centres for Disease Control and Prevention (CDC). (2022). *Drug Overdose Deaths*. https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm
3. World Health Organisation (WHO). (2023). *World Drug Report*. https://www.who.int/
4. American Psychiatric Association. (2022). *Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR)*.
5. Han, B., Jones, C. M., Einstein, E. B., Dowell, D., & Compton, W. M. (2024). Prescription opioid use disorder among adults reporting prescription opioid use with or without misuse in the United States. *Journal of Clinical Psychiatry, 85*(3), Article 24m15258. https://doi.org/10.4088/JCP.24m15258
6. Grand View Research. (2024). *Opioid Use Disorder Market Size & Trends*. https://www.grandviewresearch.com/industry-analysis/opioid-use-disorder-market
7. Hazelden Betty Ford Foundation. (2023). *Racial/Ethnic Disparities in Addiction*. https://www.hazeldenbettyford.org/research-studies/addiction-research/ethnic-health-disparities
8. National Institute on Drug Abuse (NIDA). (2025). *IC Fact Sheet*. https://nida.nih.gov/about-nida/legislative-activities/budget-information/fiscal-year-2025-budget-information-congressional-justification-national-institute-drug-abuse/ic-fact-sheet-2025
9. SHADAC. (2024). *The Evolving Opioid Epidemic in the United States*. https://www.shadac.org/opioid-epidemic-united-states